Aquestive Therapeutics Inc (NASDAQ: AQST) kicked off on Monday, up 1.49% from the previous trading day, before settling in for the closing price of $2.69. Over the past 52 weeks, AQST has traded in a range of $1.25-$6.23.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -4.81% over the last five years. While this was happening, its average annual earnings per share was recorded -281.73%. With a float of $79.75 million, this company’s outstanding shares have now reached $91.04 million.
The firm has a total of 135 workers. Let’s measure their productivity.
Aquestive Therapeutics Inc (AQST) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Aquestive Therapeutics Inc is 12.40%, while institutional ownership is 39.45%. The most recent insider transaction that took place on Mar 15 ’24, was worth 300,000. In this transaction Chief Innovation/Tech Officer of this company sold 50,000 shares at a rate of $6.00, taking the stock ownership to the 984,476 shares. Before that another transaction happened on Mar 08 ’24, when Company’s Chief Innovation/Tech Officer sold 25,000 for $5.19, making the entire transaction worth $129,685. This insider now owns 1,040,371 shares in total.
Aquestive Therapeutics Inc (AQST) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 3/31/2024, the organization reported -0.1 earnings per share (EPS), higher than consensus estimate (set at -0.12) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -281.73% per share during the next fiscal year.
Aquestive Therapeutics Inc (NASDAQ: AQST) Trading Performance Indicators
Take a look at Aquestive Therapeutics Inc’s (AQST) current performance indicators. Last quarter, stock had a quick ratio of 5.85. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.83.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.43, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.43 in one year’s time.
Technical Analysis of Aquestive Therapeutics Inc (AQST)
Analysing the last 5-days average volume posted by the [Aquestive Therapeutics Inc, AQST], we can find that recorded value of 0.93 million was lower than the volume posted last year of 1.99 million. As of the previous 9 days, the stock’s Stochastic %D was 31.63%. Additionally, its Average True Range was 0.19.
During the past 100 days, Aquestive Therapeutics Inc’s (AQST) raw stochastic average was set at 10.49%, which indicates a significant decrease from 30.19% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.62% in the past 14 days, which was lower than the 93.69% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.39, while its 200-day Moving Average is $2.69. Now, the first resistance to watch is $2.79. This is followed by the second major resistance level at $2.86. The third major resistance level sits at $2.96. If the price goes on to break the first support level at $2.63, it is likely to go to the next support level at $2.53. Now, if the price goes above the second support level, the third support stands at $2.46.
Aquestive Therapeutics Inc (NASDAQ: AQST) Key Stats
The company with the Market Capitalisation of 248.54 million has total of 91,039K Shares Outstanding. Its annual sales at the moment are 50,580 K in contrast with the sum of -7,870 K annual income. Company’s last quarter sales were recorded 12,050 K and last quarter income was -12,830 K.
